A Phase 2 interventional study of Urolithin A (Mitopure) and Placebo in Copd, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Completed at 3 sites in Canada. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Pulmonary Disease, Chronic Obstructive by McGill University Health Centre/Research Institute of the McGill University Health Centre — 2 open to participants now, 2 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · McGill University Health Centre/Research Institute of the McGill University Health Centre.
Among the 14 studies in Pulmonary Disease, Chronic Obstructive by McGill University Health Centre/Research Institute of the McGill University Health Centre, this one is the only one that started in 2024, is the only one in phase 2, and was the 10th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 14 studies in Pulmonary Disease, Chronic Obstructive by McGill University Health Centre/Research Institute of the McGill University Health Centre are open now, in 1 country. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 40+
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 40+
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 2 · Phase 4 1
First in 2008; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 35 across the 8 interventional studies, 44 across the 6 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
McGill University Health Centre/Research Institute of the McGill University Health Centre is the lead sponsor of 422 studies on the registry; 106 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Pulmonary Disease, Chronic Obstructive by McGill University Health Centre/Research Institute of the McGill University Health Centre, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic obstructive pulmonary disease (COPD) is a very common and chronic lung condition and is a leading cause of morbidity and death. These patients have persistent breathlessness and exercise intolerance, affecting their ability to carry out routine daily tasks. Standard COPD treatments include medicines/puffers as well as participation in a Pulmonary Rehabilitation (PR) program. PR programs are delivered by a diverse team of healthcare experts in exercise and nutrition. It is possible that an emerging nutritional oral supplement could target the muscular dysfunction seen in patients with COPD in part by promoting better working mitochondria, the energy 'engine' of muscle. A series of recently published studies in sedentary adults and in older adults have demonstrated the safety, tolerability, and potential clinical effectiveness of this supplement.
In this regard, the investigators plan to lead a large randomized controlled trial (RCT) to test whether oral supplementation in patients with COPD who are also participating in a standard PR program will improve overall exercise performance. The investigators will also test muscle strength, cognition, body composition, and other clinically important outcomes such as quality of life. Lastly, the investigators will use muscle tissue from a subgroup of volunteers to investigate the effect on muscle/mitochondrial structure/function.
The focus is actually the critical 'first step' before the larger RCT: a pilot and feasibility study on a smaller number of participants with COPD, as an important proof-of-concept that the larger study can, and should, be conducted.
The main objectives for this pilot feasibility study are to document recruitment rates, collect information on participant acceptability of tests, establish the capacity to run the RCT at our site, to demonstrate successful molecular testing of specimens, and to generate pilot data for the outcomes being tested in the larger subsequent RCT.
The overarching goal for the 'larger', future project will be to determine the effect of the oral supplement on exercise capacity, muscle strength, mitochondrial function, health-related quality of life, cognition, symptom burden, and safety/adherence in patients with COPD who are participating in a Pulmonary Rehabilitation program. The goal of the present research project is to complete a pilot and feasibility study testing the same clinical outcomes on a smaller sample of eligible study participants during which participants receive the intervention for 8 weeks.
The primary objective is to determine whether administration of the oral supplement during participation in a standard multi-week in-person Pulmonary Rehabilitation (PR) program is associated with an improvement in exercise endurance capacity in patients with COPD, compared with PR participation and placebo supplementation.
The secondary objectives are to determine the effect of the oral supplement on i) global conditioning and exercise capacity; ii) muscle strength; iii) mitochondrial function; iv) body composition; v) quality of life and burden of disease; vi) cognition; vii) adverse events/complications and adherence, and viii) blood levels of Urolithin A.
We hypothesize that patients with COPD receiving oral supplementation during PR participation will demonstrate an improvement in Constant Work Rate Exercise Test (CRWET) time after 8 weeks when compared to patients with COPD who receive placebo and PR participation.
The criteria were revised on the registry on Oct 15, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will participate in a standard PR program and will receive placebo.
Other: Placebo
Participants will participate in a standard PR program and will receive the oral supplement.
Dietary Supplement: Urolithin A (Mitopure)
Compound belonging to the 'urolithin' class. First discovered over 40 years ago as a gut-derived metabolite in rats and subsequently in humans. A food and dietary ingredient, and more specifically, a post-biotic compound. Derived from ellagitannins, which are present in foods such as pomegranate, berries, and walnuts. An 'inducer' of mitophagy.
Placebo.
Primary Feasibility Outcome: Recruitment rate
The proportion of participants who agree to participate out of the number of all potential participants asked to participate. Recruitment rate represents the primary feasibility outcome of the current pilot RCT.
Time frame: From study launch to study completion at every visit until post-intervention visit (average week 14)
Constant Work Rate Exercise Test (CWRET)
Exercise test whereby the workload is constant and is calculated as a percentage of the peak power output observed in the incremental test. CWRET time represents the pre-specified primary outcome of the planned main RCT.
Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
Feasibility Outcome: Attrition rate
The percentage of participants who do not complete the study out of all participants randomized. Outcome of the current pilot RCT.
Time frame: From study launch to study completion at every visit until post-intervention visit (average week 14)
Adherence/Fidelity Outcome: Differences in dosed missed
The total number of doses missed will be recorded and reported. Outcome of the current pilot RCT.
Time frame: 8 weeks
Feasibility Outcome: Study test completion rate
Study test completion rate of each assessment (percentage of participants who complete each assessment). Outcome of the current pilot RCT.
Time frame: From study launch to study completion at every visit until post-intervention visit (average week 14)
Safety Outcome: Adverse events
Adverse events (AEs) will be monitored from the signing of the Informed Consent Form (ICF) through completion of study participation. If any AEs do occur, study participants will be followed until symptoms have resolved or have returned to baseline levels. All outstanding AEs will be followed until resolution or until the participant's last study visit.
Time frame: 14 weeks
6-Minute Walk Test (6MWT)
6-Minute Walk Distance (6MWD) obtained on a standard 6MWT.
Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
Quadriceps strength
4-second maximum quadriceps strength test.
Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
Disease-specific impact on quality of life
St. George's respiratory questionnaire (SGRQ) score is a patient reported outcome measuring quality of life from 0-100 where higher scores indicate worse quality of life.
Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
Burden of disease
COPD assessment test (CAT) scores is a patient reported outcome measuring COPD symptom burden from 0-40 where higher scores indicate worse symptom burden.
Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
Body composition
Dual X-ray absorptiometry (DXA) scan
Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
Body impedance
Bioelectrical impedance assay (BIA)
Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
Isokinetic cycling peak power output (PPO)
Isokinetic cycling PPO is measured during a ≤10-second cycling effort on a stationary isokinetic bicycle.
Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
Cognition
Stroop test
Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
Adherence/Fidelity Outcome: Blood levels of the intervention
Blood levels of Urolithin A will be collected at the mid-point of the study.
Time frame: Day 28
Feasibility Outcome: Muscle biopsy volunteer rate
Proportion of participants who consent to the optional muscle biopsy out of those who also meet eligibility criteria for the optional muscle biopsy.
Time frame: From study launch to study completion at every visit until post-intervention visit (average week 14)
Exploratory Outcome: Mitochondrial function
Fresh samples
Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
Exploratory Outcome: Muscle histology
Stains for mitochondrial markers (including succinate dehydrogenase (SDH)): post-intervention in comparison to pre-intervention.
Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
Exploratory Outcome: Specific protein detection
Targeted Western blot analysis for proteins related to mitochondrial function: post-intervention in comparison to pre-intervention.
Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
Exploratory Outcome: Tissue microscopy
Transmission electron microscopy for assessment of morphology of mitochondria: post-intervention in comparison to pre-intervention.
Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
Exploratory Outcome: Tissue microscopy
Transmission electron microscopy for assessment of number of mitochondria: post-intervention in comparison to pre-intervention.
Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
Exploratory Outcome: RNA analyses
Specific mRNA transcript changes related to mitochondrial function and whole transcriptome changes: post-intervention in comparison to pre-intervention.
Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
Plan to share: No — Due to data privacy regulations, individual participant data collected during this study is not publicly accessible. However, access to anonymized data may be granted upon evaluation by the trial management group. Additional documents will also be available upon inquiry. All requests should be directed to the Principal Investigator (BAR).
No publications or documents are linked to this record.
Ran from Mar 2024 to primary completion in Jul 2026, 28 months.
Of 47 non-industry phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 63. This study's 28 months is below that.
Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 10 and three quarters within 31.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Mar 2025 → Jul 2026 and completion May 2025 → Jul 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Urolithin A Supplement
Pulmonary Disease, Chronic Obstructive →
McGill University Health Centre/Research Institute of the McGill University Health Centre →